January 9th, 2026.
New early clinical trial data released by uniQure indicate that an experimental gene therapy for Huntington’s disease may dramatically slow the progression of the fatal neurodegenerative disorder, with treated patients showing up to a 75% reduction in expected disease progression.
The therapy, known as AMT-130, is a one-time gene therapy administered directly into targeted regions of the brain through a neurosurgical procedure. Rather than attempting to manage symptoms after damage has occurred, the treatment is designed to intervene at the genetic level by reducing production of the mutant huntingtin protein that drives the disease.
According to uniQure, the data come from ongoing Phase I/II clinical trials evaluating the safety and biological activity of AMT-130 in adults with early-stage Huntington’s disease. Participants received a single administration of the therapy and were followed longitudinally using established clinical and functional assessment tools.
The company reports that patients treated with AMT-130 demonstrated substantially slower functional decline when compared with matched natural history control data; in some analyses, disease progression appeared to be reduced by approximately 75% over the observed period. While the trial was not designed to prove efficacy as a primary endpoint, the strength and consistency of the signal have drawn attention within the neurodegenerative research community.
AMT-130 works by delivering genetic material that suppresses expression of the toxic huntingtin protein in the brain. This approach represents a departure from traditional drug therapies, which require repeated dosing and often struggle to cross the blood–brain barrier; instead, the goal is long-term modification of disease biology following a single treatment.
Importantly, uniQure emphasizes that the trial remains focused on safety and tolerability, and that larger, later-stage trials will be required to confirm clinical benefit. Even so, the company describes the findings as encouraging, particularly given the lack of disease-modifying treatments currently available for Huntington’s disease.
Huntington’s disease is a hereditary condition that leads to progressive loss of movement control, cognitive decline, and psychiatric symptoms; it is uniformly fatal and typically worsens over a period of 10 to 25 years. Existing treatments address symptoms but do not alter the underlying disease course.
While researchers caution that early-stage results should be interpreted carefully, the AMT-130 data suggest that gene-based interventions may hold real potential to change the trajectory of Huntington’s disease. For patients and families facing a condition long defined by inevitability, even partial slowing represents a meaningful shift.
Further updates from the ongoing trials are expected as additional participants reach longer follow-up milestones and as regulatory discussions continue regarding next-stage studies.
Sources
Primary First-Hand Sources
• uniQure — AMT-130 Huntington’s Disease Program
• uniQure — AMT-130 Patient and Clinical Trial Information
• ClinicalTrials.gov — Study NCT04120493 (as referenced by uniQure)
Leave a Reply